- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
CT-1119 is an ex vivo gene-modified autologous CAR-Monocyte cellular therapy to target mesothelin-positive solid tumors.
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. The lead program is an anti-glypican 3 (GPC3) in vivo CAR-M therapy for the treatment of hepatocellular carcinoma (HCC).
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in vivo therapies to address multiple cancer targets. Five targets have been nominated (including the lead), with the option to identify an additional 7 oncology targets.
CT-2401 leverages TIM4 mRNA-loaded Kupffer cell tropic LNPs to restore TIM4 expression, repairing efferocytosis and dramatically reducing fibrosis.
In collaboration with Moderna, Carisma has two in vivo CAR-M research programs for the treatment of autoimmune diseases associated with two distinct targets where there is significant unmet medical need.